SARS Test Available From CDC Within Weeks; Mutations May Hinder Diagnosis
This article was originally published in The Gray Sheet
Executive Summary
CDC remains cautious about the viability of a SARS diagnostic, citing the coronavirus' proclivity for mutations that may threaten performance of polymerase chain reaction (PCR) and antibody tests
You may also be interested in...
NIH, FDA Respond To SARS Epidemic: Diagnostics, Medical Supply Stockpile
A sensitive and specific diagnostic for severe acute respiratory syndrome will be available in six to 12 months, NIAID Director Anthony Fauci, MD, averred at a May 7 House Energy & Commerce/Oversight & Investigations Subcommittee hearing
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.